| 115.45 3.65 (3.26%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 136.65 |
1-year : | 159.61 |
| Resists | First : | 117 |
Second : | 136.65 |
| Pivot price | 106.88 |
|||
| Supports | First : | 106.6 |
Second : | 100.18 |
| MAs | MA(5) : | 109.87 |
MA(20) : | 106.31 |
| MA(100) : | 116.65  |
MA(250) : | 122.31 |
|
| MACD | MACD : | 0 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 87.3 |
D(3) : | 74.9 |
| RSI | RSI(14): 62.4 |
|||
| 52-week | High : | 178.59 | Low : | 100.18 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TFX ] has closed Bollinger Bands are 24.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 117.09 - 117.64 | 117.64 - 118.16 |
| Low: | 109.26 - 109.88 | 109.88 - 110.46 |
| Close: | 114.41 - 115.41 | 115.41 - 116.34 |
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Thu, 19 Feb 2026
Earnings Preview: Teleflex (TFX) Q4 Earnings Expected to Decline - Finviz
Tue, 17 Feb 2026
Teleflex to Host Q4 2025 Earnings Call on February 26, 2026 - Intellectia AI
Tue, 17 Feb 2026
Teleflex Announces Fourth Quarter 2025 Earnings Conference Call Information - Business Wire
Tue, 17 Feb 2026
Teleflex (TFX) Fell on Spin-Off Announcements - MSN
Mon, 16 Feb 2026
Teleflex Incorporated (TFX) Stock Analysis: Evaluating a 24.58% Potential Upside Amid Healthcare Innovations - DirectorsTalk Interviews
Mon, 09 Feb 2026
Teleflex Inc (TFX) Shares Gap Down to $104.71 on Feb 9 - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 44 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 106.4 (%) |
| Shares Short | 1,900 (K) |
| Shares Short P.Month | 1,720 (K) |
| EPS | -7.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 86.48 |
| Profit Margin | -10.3 % |
| Operating Margin | 12.3 % |
| Return on Assets (ttm) | 4.9 % |
| Return on Equity (ttm) | -8 % |
| Qtrly Rev. Growth | 19.3 % |
| Gross Profit (p.s.) | 38.92 |
| Sales Per Share | 72.18 |
| EBITDA (p.s.) | 20.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 391 (M) |
| Levered Free Cash Flow | 243 (M) |
| PE Ratio | -16.27 |
| PEG Ratio | 0 |
| Price to Book value | 1.33 |
| Price to Sales | 1.59 |
| Price to Cash Flow | 13.04 |
| Dividend | 0.34 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|